Replies to post #160669 on Biotech Values

[jq1234]

With data like these in hand, why would they still include 24-week arms in fixed dose combination with or without RBV in ION-1 and ION-2 ph3 trials?

[mcbio]

Interim-data table from GILD’s phase-2 LONESTAR study

One important question to keep in mind is how likely is that very good 8-week treatment duration with SVR8 number of 95% in the sofosbuvir+ledipasvir arm or the 100% SVR8 with addition of ribavirin likely to translate into SVR12 and beyond? I ask in connection with the prior ABBV data that showed relapse later on despite the initial very promising earlier SVR data. While this data is indeed very promising, we certainly need to see further data.